LOUISVILLE, Ky., Dec. 12, 2016 /PRNewswire/ -- Eurofins Genomics today announced the U.S. launch of its EXTREmer oligonucleotides, extremely long oligos that are developed using high-fidelity synthesis chemistry on the company’s new DNA synthesis platform. Designed for synthetic biology, next-generation DNA sequencing and other growing applications, these oligos are provided at low yield and with low error rates, and can lead to increased success and reduced timelines in a range of everyday molecular biology experiments.
Among the benefits to researchers, EXTREmers allow for construction of genes with segments of low sequence variability that would be difficult or impossible to assemble using shorter oligos. They can also be used directly as a template for in vitro transcription of RNA molecules, saving time and effort for scientists who previously had to ligate smaller DNA oligos to form the template. In addition, they can be used for introducing large-scale or multi-site mutations without waiting days or weeks to go through multiple cycles of site-directed mutagenesis. The new service will also be helpful for generating oligos for DNA-directed RNA interference, capture probes, or control standards in qPCR experiments, among other demanding applications.
“EXTREmers are produced using our newly developed, high-throughput oligonucleotide synthesizer that incorporates highly efficient reagent delivery systems, cycle-optimization, and downstream processes to ensure that each coupling reaction achieves greater than 99.5% efficiency,” said Jeff Nelson, Head of Process Development for High-Throughput Synthesis at Eurofins Genomics. “Our initial experiments have shown that these oligos offer a higher probability of success than those offered by comparable products when evaluated in cloning applications.”
More information about EXTREmers is available at http://www.eurofinsgenomics.com/en/products/dnarna-synthesis/extremers.aspx.
About Eurofins Genomics
Eurofins Genomics company is an international provider of DNA sequencing services, genotyping services, DNA synthesis products, and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological, and research markets. Eurofins Genomics operates leading R&D and production sites in the USA, Canada, Germany, India, and Japan.
Eurofins Genomics is the genomic services brand of the Eurofins Group, the worldwide leader in food, environmental and pharmaceutical testing. With 25,000 staff in over 250 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
© Eurofins MWG Operon, LLC, a Eurofins Genomics Company
Contacts:
Media:
Nicole Litchfield
Bioscribe, Inc.
415-793-6468
nicole@bioscribe.com
Company:
James Corne
Eurofins Genomics
502-302-6351
jamescorne@eurofins.com
Logo - http://photos.prnewswire.com/prnh/20161004/415145LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eurofins-genomics-launches-extremers--extremely-long-oligonucleotides-300376190.html
SOURCE Eurofins Genomics
